ANTI-AGEING
a significant reduction in beta-galactosidase activity at P11, with a decrease of 24% (p<0.05). These results suggest that the new ingredient effectively delays cellular senescence and reduces the accumulation of senescent cells during the late stages of replication. At the P5 stage, minimal expression of the
p16 protein was detected, consistent with low levels of cellular senescence. By P11, untreated cells showed a significant increase in p16 protein levels, indicating an increase in senescent cells. However, treatment with the plant extract throughout the culture process resulted in a significant decrease in p16 protein expression at P11, with a reduction of 34% (p<0.01). These results highlight the ability of
the bioactive to effectively combat cellular senescence, reduce the number of senescent cells over time and mitigate the effects of replicative ageing, suggesting that the new product effectively delays the onset of senescence and contributes to improved skin longevity.
Senostatic effect: control of SASP Senostatic effect refers to the ability of certain substances or interventions to inhibit or attenuate the expression of SASP. Senescent fibroblasts are known to release a collection of molecules collectively referred to as the Senescence-Associated Secretory Phenotype (SASP). These include matrix metalloproteinases (MMPs), such as MMP1, which degrade collagen and compromise skin
MMP1 release
120 100 80 60 40 20 0
NaBu
Statistics: Mean ± SEM n=3 One way ANOVA vs NaBu (*) p<0.05
85
-68%
-91%
(*) (*) NaBu +
Lysimachia extract 0.025%
NaBu +
Lysimachia extract 0.05%
Figure 2: Evaluation of MMP1 release after induction of fibroblast senescence in the presence or absence of the Lysimachia extract at different concentrations
structural integrity, and pro-inflammatory interleukins (IL-6 and IL-8), which accelerate skin ageing processes. To investigate the senostatic potential of
the Lysimachia extract, the release of MMP1 was measured in fibroblasts exposed to a senescence inducer, sodium butyrate (NaBu), which is known to increase MMP production. The experiment was designed to compare
the effects of the stressor alone (control) with those observed when the stressor was applied together with the new bioactive. Fibroblasts were grown to confluence in DMEM medium (Dulbecco’s Modified Eagle Medium, a nutrient-rich solution for culturing cells in vitro), and then treated with or without the new ingredient for 24 hours. Senescence was then induced by exposure to sodium
www.personalcaremagazine.com
April 2025 PERSONAL CARE
% of MMP1
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
